9079-5 |
Protein intake |
Mass |
^Patient |
Pt |
Qn |
Estimated |
|
ACTIVE |
Protein intake Estimated |
|
MIN |
DefinitionDescription |
|
|
g |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9079-5 |
|
Estimated |
|
|
|
|
|
|
0 |
Protein intake Est |
|
|
|
|
|
Est; estimation; IO_INTAKE_SALTS+CALORIES; Point in time; PR; Prot; QNT; Quan; Quant; Quantitative; Random |
2.48 |
1.0i |
|
|
|
|
|
|
|
g |
|
|
|
0 |
90790-7 |
Note |
Find |
{Setting} |
Pt |
Doc |
Podiatry.resident |
|
ACTIVE |
Podiatry Resident Note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
90790-7 |
|
Podiatry.resident |
|
|
Both |
|
|
|
0 |
Podiatry Res Note |
|
|
|
|
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Podiatry Res; Point in time; Random; Visit note |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90791-5 |
Note |
Find |
{Setting} |
Pt |
Doc |
Physical therapy.resident |
|
ACTIVE |
Physical therapy Resident Note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
90791-5 |
|
Physical therapy.resident |
|
|
Both |
|
|
|
0 |
PT Res Note |
|
|
|
|
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; PT; PT Res; Random; Visit note |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90792-3 |
Preoperative evaluation and management note |
Find |
{Setting} |
Pt |
Doc |
Podiatry.attending |
|
ACTIVE |
Podiatry Attending Preoperative evaluation and management note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
90792-3 |
|
Podiatry.attending |
|
|
Both |
|
|
|
0 |
Podiatry Attend Pre-op note |
|
|
|
|
|
Assessment; Clinical encounter note; DOC.ONT; Document; E/M note; Encounter; Eval; Evaluation and management; Evaluation and management note; Finding; Findings; H&P; History and physical; notes; Podiatry Attend; Point in time; Pre-Op; Pre-op note; Pre-Operative; Random; Visit note |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90793-1 |
Note |
Find |
{Setting} |
Pt |
Doc |
Podiatry.attending |
|
ACTIVE |
Podiatry Attending Note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
90793-1 |
|
Podiatry.attending |
|
|
Both |
|
|
|
0 |
Podiatry Attend Note |
|
|
|
|
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Podiatry Attend; Point in time; Random; Visit note |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90794-9 |
Vedolizumab & Vedolizumab Ab Panel |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Vedolizumab and Vedolizumab Ab panel [Mass/volume] - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
90794-9 |
|
|
|
|
Order |
|
|
|
0 |
Vedol + Vedol Ab Pnl SerPl-mCnc |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Entyvio; Level; Mass concentration; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Vedol; Vedolizumab + Vedolizumab Ab Pnl; VEMAB |
2.65 |
2.65 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
90795-6 |
Levothyroxine absorption panel |
- |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Levothyroxine absorption panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
90795-6 |
|
|
|
|
Order |
|
|
|
0 |
Levothyroxine absorption pnl SerPl |
|
|
|
|
|
Absorp; c99; CHEMISTRY.CHALLENGE TESTING; Levothyroxine absorption pnl; L-thyroxine; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.65 |
2.65 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
90796-4 |
Thyroxine^1H post dose levothyroxine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyroxine (T4) [Mass/volume] in Serum or Plasma --1 hours post dose levothyroxine |
|
ADD |
DefinitionDescription |
|
|
mcg/dL |
|
|
|
|
|
|
CHAL |
|
90796-4 |
|
|
|
|
Observation |
|
|
|
0 |
T4 1h p levo SerPl-mCnc |
|
|
|
|
|
1 hour; 1.0Hr; 1h p levo; 60 min; 60 minutes; 60M; 60min; After; c99; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Levothyroxine; Levo-thyroxine; L-thyroxine; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; T4; T-4; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4 |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
90797-2 |
Thyroxine^2H post dose levothyroxine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyroxine (T4) [Mass/volume] in Serum or Plasma --2 hours post dose levothyroxine |
|
ADD |
DefinitionDescription |
|
|
mcg/dL |
|
|
|
|
|
|
CHAL |
|
90797-2 |
|
|
|
|
Observation |
|
|
|
0 |
T4 2h p levo SerPl-mCnc |
|
|
|
|
|
120 min; 120 minutes; 120min; 2 hours; 2h p levo; After; c99; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Levothyroxine; Levo-thyroxine; L-thyroxine; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; T4; T-4; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4 |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
90798-0 |
Thyroxine^3H post dose levothyroxine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyroxine (T4) [Mass/volume] in Serum or Plasma --3 hours post dose levothyroxine |
|
ADD |
DefinitionDescription |
|
|
mcg/dL |
|
|
|
|
|
|
CHAL |
|
90798-0 |
|
|
|
|
Observation |
|
|
|
0 |
T4 3h p levo SerPl-mCnc |
|
|
|
|
|
3h p levo; After; c99; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Levothyroxine; Levo-thyroxine; L-thyroxine; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; T4; T-4; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4 |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
90799-8 |
Thyroxine^4H post dose levothyroxine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyroxine (T4) [Mass/volume] in Serum or Plasma --4 hours post dose levothyroxine |
|
ADD |
DefinitionDescription |
|
|
mcg/dL |
|
|
|
|
|
|
CHAL |
|
90799-8 |
|
|
|
|
Observation |
|
|
|
0 |
T4 4h p levo SerPl-mCnc |
|
|
|
|
|
4h p levo; After; c99; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Levothyroxine; Levo-thyroxine; L-thyroxine; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; T4; T-4; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4 |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
908-4 |
Ax Ab |
PrThr |
Ser/Plas^BPU |
Pt |
Ord |
|
|
ACTIVE |
Ax Ab [Presence] in Serum or Plasma from Blood product unit |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
908-4 |
|
|
|
|
Observation |
|
|
|
0 |
Ax Ab SerPl BPU Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Ao; Autoantibodies; Autoantibody; BLOOD BANK; Blood product unit; Blood Product Unit (Pack); Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPl^bpu; SerPlas; Serum; Serum or plasma; SR |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
9080-3 |
Protein intake |
Mass |
^Patient |
Pt |
Qn |
Measured |
|
ACTIVE |
Protein intake Measured |
|
MIN |
DefinitionDescription |
|
|
g |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9080-3 |
|
Measured |
|
|
|
|
|
|
0 |
Protein intake Measured |
|
|
|
|
|
IO_INTAKE_SALTS+CALORIES; Point in time; PR; Prot; QNT; Quan; Quant; Quantitative; Random |
2.48 |
1.0i |
|
|
|
|
|
|
|
g |
|
|
|
0 |
90800-4 |
Thyroxine^6H post dose levothyroxine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyroxine (T4) [Mass/volume] in Serum or Plasma --6 hours post dose levothyroxine |
|
ADD |
DefinitionDescription |
|
|
mcg/dL |
|
|
|
|
|
|
CHAL |
|
90800-4 |
|
|
|
|
Observation |
|
|
|
0 |
T4 6h p levo SerPl-mCnc |
|
|
|
|
|
>6h; 6h p levo; After; c99; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Levothyroxine; Levo-thyroxine; L-thyroxine; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; T4; T-4; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4 |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
90801-2 |
Thyrotropin^6H post dose levothyroxine |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyrotropin [Units/volume] in Serum or Plasma --6 hours post dose levothyroxine |
|
ADD |
DefinitionDescription |
|
|
mIU/mL |
|
|
|
|
|
|
CHAL |
|
90801-2 |
|
|
|
|
Observation |
|
|
|
0 |
TSH 6h p levo SerPl-aCnc |
|
|
|
|
|
>6h; 6h p levo; After; Arbitrary concentration; c99; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; L-thyroxine; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thyroid stimulating hormone; Thyrotropic hormone; TSH |
2.65 |
2.65 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
90802-0 |
Medication volume of distribution |
Vol |
^Patient |
Pt |
Qn |
Calculated |
|
ACTIVE |
Medication volume of distribution Calculated |
|
ADD |
DefinitionDescription |
|
|
L |
|
|
Dose/Concentration at time 0 |
|
|
|
MEDS |
|
90802-0 |
|
Calculated |
|
|
Observation |
|
|
|
0 |
Med Vd Calc |
|
|
|
|
|
Calc; Calculation; Med Vd; MEDS; Point in time; QNT; Quan; Quant; Quantitative; Random; Vol; Volume |
2.65 |
2.65 |
|
|
|
|
|
|
|
L |
|
|
|
0 |
90803-8 |
Peak concentration post XXX challenge - baseline concentration increment |
MCncDiff |
Ser/Plas |
Pt |
Qn |
Calculated |
|
ACTIVE |
Post-challenge peak - baseline concentration increment [Mass concentration difference] in Serum or Plasma by calculation |
|
ADD |
DefinitionDescription |
|
|
ug/dL |
|
|
Concentration increment = Peak concentration - baseline concentration |
|
|
|
DRUG/TOX |
|
90803-8 |
|
Calculated |
|
|
Observation |
|
|
|
0 |
Conc increment SerPl Calc-MCDiff |
|
|
|
|
|
After; Calc; Calculation; Conc increment; DRUG/TOXICOLOGY; Drugs; MCDiff; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
90804-6 |
Levothyroxine absorption |
MFr |
Ser/Plas |
Pt |
Qn |
Calculated |
|
ACTIVE |
Levothyroxine absorption in Serum or Plasma by calculation |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
[(Incremental increase in T4 x 10)(Volume of distribution x 100)]/Levothyroxine dose administered |
|
|
|
CHAL |
|
90804-6 |
|
Calculated |
|
|
Observation |
|
|
|
0 |
Levothyroxine absorption MFr SerPl Calc |
|
|
|
|
|
Absorp; c99; Calc; Calculation; CHEMISTRY.CHALLENGE TESTING; L-thyroxine; Mass fraction; Percent; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.65 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
90805-3 |
Vedolizumab^trough |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Vedolizumab [Mass/volume] in Serum or Plasma by LC/MS/MS --trough |
|
ADD |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
90805-3 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Vedolizumab Trough SerPl LC/MS/MS-mCnc |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Entyvio; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; Pre; Predose; Pre-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Vedol |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
90806-1 |
Candida albicans DNA |
PrThr |
Ser |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida albicans DNA [Presence] in Serum by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90806-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C albicans DNA Ser Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C albicans; C albicans DNA; Cand; Candidiasis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; m005; m5; Microbiology; Monilia; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Serum; SR; Strand Displacement Amplification; Thrush; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90807-9 |
Candida glabrata DNA |
PrThr |
Ser |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida glabrata DNA [Presence] in Serum by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90807-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C glabrata DNA Ser Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C glabrata; C glabrata DNA; Cand; Candidiasis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Serum; SR; Strand Displacement Amplification; TMA; Torulopsis glabrata; Transcription mediated amplification |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90808-7 |
Candida krusei DNA |
PrThr |
Ser |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida krusei DNA [Presence] in Serum by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90808-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C krusei DNA Ser Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C krusei; Cand; Candidiasis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Serum; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90809-5 |
Candida parapsilosis DNA |
PrThr |
Ser |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida parapsilosis DNA [Presence] in Serum by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90809-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C parap DNA Ser Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C parap; Cand; Candidiasis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Serum; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
9081-1 |
Protein intake |
MRat |
^Patient |
1H |
Qn |
|
|
ACTIVE |
Protein intake 1 hour |
|
MIN |
DefinitionDescription |
|
|
g/h |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9081-1 |
|
|
|
|
|
|
|
|
0 |
Protein intake 1h |
|
|
|
|
|
1 hour; 1.0Hr; 1HR; 60 min; 60 minutes; 60M; 60min; IO_INTAKE_SALTS+CALORIES; Mass Rate; mRate; PR; Prot; QNT; Quan; Quant; Quantitative |
2.48 |
1.0i |
|
|
|
|
|
|
|
g/h |
|
|
|
0 |
90810-3 |
Candida tropicalis DNA |
PrThr |
Ser |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida tropicalis DNA [Presence] in Serum by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90810-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C tropicls DNA Ser Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C tropicls; Cand; Candidiasis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Serum; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |